Inventiva S.A.
EPA:IVA.PA
2.08 (EUR) • At close September 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Inventiva S.A. |
Symbool | IVA.PA |
Munteenheid | EUR |
Prijs | 2.085 |
Beurswaarde | 109,193,712 |
Dividendpercentage | 0% |
52-weken bereik | 2.04 - 4.55 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Frederic Cren |
Website | https://www.inventivapharma.com |
An error occurred while fetching data.
Over Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)